Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Atyr Pharma Inc shares valued at $101,038 were purchased by SCHIMMEL PAUL on Jul 24 ’24. At $1.93 per share, SCHIMMEL PAUL acquired 52,300 shares. The insider’s holdings grew to 413,023 shares worth approximately $1.12 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, SCHIMMEL PAUL purchased 41,052 shares, netting a total of over 71,500 in proceeds. Following the buying of shares at $1.74 each, the insider now holds 354,075 shares.
Before that, SCHIMMEL PAUL had added 6,648 shares to its account. In a trade valued at $12,075, the Director bought Atyr Pharma Inc shares for $1.82 each. Upon closing the transaction, the insider’s holdings increased to 6,648 shares, worth approximately $0.98 million.
As published in their initiating research note from Wells Fargo on October 04, 2024, Atyr Pharma Inc [ATYR] has been an Overweight and the price target has been revised to $17. Analysts at Jefferies started covering the stock with ‘”a Buy”‘ outlook in a report released in early September. As of July 05, 2023, Oppenheimer has decreased its “an Outperform” rating to a “Perform” for ATYR. Earlier on October 12, 2021, RBC Capital Mkts initiated its rating. Their recommendation was “an Outperform” for ATYR stock.
Analyzing ATYR Stock Performance
During the last five days, there has been a surge of approximately 28.91%. Over the course of the year, Atyr Pharma Inc shares have jumped approximately 92.91%. Shares of the company reached a 52-week high of $2.86 on 10/16/24 and a 52-week low of $1.39 on 01/02/24. A 50-day SMA is recorded $1.90, while a 200-day SMA reached $1.79.
Support And Resistance Levels for Atyr Pharma Inc (ATYR)
According to the 24-hour chart, there is a support level at 2.56, which, if violated, would cause prices to drop to 2.40. In the upper region, resistance lies at 2.87. The next price resistance is at 3.02. RSI (Relative Strength Index) is 83.47 on the 14-day chart, showing overbought technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.52, which suggests the price will decrease in the coming days. Percent R is at 11.76%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
